Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced / metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinom

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Mdm2 Amplified, Tp53 Wild-type Biliary Tract Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Or Other Selected Solid Tumours
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Biliary tract adenocarcinoma, pancreatic ductal adenocarcinoma, lung adenocarcinoma, or urothelial bladder cancer
    2. Be able to provide samples of tumor tissue preserved in a specific way (using formalin and paraffin)
    3. Adequate

You may not be eligible for this study if the following are true:

    1. Currently experiencing active bleeding, have a significant risk of hemorrhage (such as a history of severe gastrointestinal bleeding or a previous hemorrhagic stroke), or have a current bleeding disorder
    2. A major surgery within four we

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.